- Home
- SXTC vs VTYX Comparison
SXTC vs VTYX Comparison
Compare SXTC & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- VTYX
- Stock Information
- Founded
- SXTC 2005
- VTYX 2018
- Country
- SXTC China
- VTYX United States
- Employees
- SXTC N/A
- VTYX N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SXTC Health Care
- VTYX Health Care
- Exchange
- SXTC Nasdaq
- VTYX Nasdaq
- Market Cap
- SXTC 184.5M
- VTYX 154.9M
- IPO Year
- SXTC 2019
- VTYX 2021
- Fundamental
- Price
- SXTC N/A
- VTYX $3.83
- Analyst Decision
- SXTC
- VTYX Buy
- Analyst Count
- SXTC 0
- VTYX 3
- Target Price
- SXTC N/A
- VTYX $10.00
- AVG Volume (30 Days)
- SXTC 102.1K
- VTYX 1.4M
- Earning Date
- SXTC 01-01-0001
- VTYX 11-06-2025
- Dividend Yield
- SXTC N/A
- VTYX N/A
- EPS Growth
- SXTC N/A
- VTYX N/A
- EPS
- SXTC N/A
- VTYX N/A
- Revenue
- SXTC $1,740,907.00
- VTYX N/A
- Revenue This Year
- SXTC N/A
- VTYX N/A
- Revenue Next Year
- SXTC N/A
- VTYX N/A
- P/E Ratio
- SXTC N/A
- VTYX N/A
- Revenue Growth
- SXTC N/A
- VTYX N/A
- 52 Week Low
- SXTC $0.95
- VTYX $0.78
- 52 Week High
- SXTC $7.84
- VTYX $4.05
- Technical
- Relative Strength Index (RSI)
- SXTC N/A
- VTYX 72.30
- Support Level
- SXTC N/A
- VTYX $2.64
- Resistance Level
- SXTC N/A
- VTYX $3.92
- Average True Range (ATR)
- SXTC 0.00
- VTYX 0.31
- MACD
- SXTC 0.00
- VTYX 0.13
- Stochastic Oscillator
- SXTC 0.00
- VTYX 90.29
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.